Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,912 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bleeding Disorder Clear all
Completed No phase listed Observational Accepts healthy volunteers

High-Shear Microfluidic Thrombosis Assay

NCT02422810
View directory record Official record
Conditions
Coagulation Defects, Other and Unspecified
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
45 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 21, 2026, 7:02 AM EDT
Terminated Phase 1 Interventional Results available

Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage

NCT02687191
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
PF-05230907
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 79 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura

NCT01554514
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
rituximab
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Anti-VEGF vs. Prompt Vitrectomy for VH From PDR

NCT02858076
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy, Vitreous Hemorrhage
Interventions
2-mg Intravitreous Aflibercept Injection, Prompt Vitrectomy Plus Panretinal Photocoagulation
Drug · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
60
States / cities
Campbell, California • Glendale, California • Huntington Beach, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Not applicable Interventional Results available

Clinical Trial of Factor XIII (FXIII) Concentrate

NCT00640289
View directory record Official record
Conditions
Hemophilia, Factor XIII Deficiency
Interventions
Fibrogammin P
Drug
Lead sponsor
Children's Hospital of Orange County
Other
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of BAX 888 in Male Adults With Severe Hemophilia A

NCT03370172
View directory record Official record
Conditions
Hemophilia A
Interventions
BAX 888
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 21, 2026, 7:02 AM EDT
Terminated Phase 3 Interventional Results available

Initial Treatment of Patients With Immune Thrombocytopenic Purpura

NCT00991939
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Dexamethasone USP Micronized, Prednisone
Drug
Lead sponsor
Carelon Research
Other
Eligibility
15 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
18
States / cities
New Orleans, Louisiana • Baltimore, Maryland • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants

NCT01511939
View directory record Official record
Conditions
Osteoarthritis of the Knee, Coagulopathy
Interventions
Pennsaid
Drug
Lead sponsor
Nathan Wei, MD, FACP, FACR:
Other
Eligibility
55 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Mixhers HERTIME Supplements on Menstrual Symptoms

NCT06136104
View directory record Official record
Conditions
Healthy, Premenstrual Dysphoric Disorder, Premenstrual Syndrome
Interventions
Mixhers HERTIME, Placebo
Dietary Supplement
Lead sponsor
Midwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Glendale, Arizona
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

NCT01351025
View directory record Official record
Conditions
HIV-1 Infection
Interventions
atorvastatin, placebo for atorvastin
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Not applicable Interventional Results available

Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA

NCT04816591
View directory record Official record
Conditions
Chronic Subdural Hematoma
Interventions
Experimental: Interventional Cohort: TRUFILL n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System, Standard of Care Surgery, Experimental: Interventional Cohort: TRUFILL n-BCA Liquid Embolic System, Standard of Care Medical Management
Device · Other
Lead sponsor
Cerenovus, Part of DePuy Synthes Products, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Walnut Creek, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 7:02 AM EDT
Recruiting Not applicable Interventional

Auricular VNS Following Subarachnoid Hemorrhage

NCT04557618
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Auricular Vagus Nerve Stimulation, Sham Auricular Vagus nerve Stimulation
Device
Lead sponsor
Anna Huguenard
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 21, 2026, 7:02 AM EDT
Not yet recruiting Not applicable Interventional

Comparative Study of Embolic Agents in Patients With Subdural Hemorrhage Undergoing Middle Meningeal Artery (MMA) Embolization

NCT07757113
View directory record Official record
Conditions
Chronic Subdural Hematoma, Stroke, Middle Meningeal Artery Embolization
Interventions
Particles (polyvinyl alcohol or similar microspheres), Liquid Embolics (Onyx, n-BCA, or equivalent), Phenox Coils (Avenir UNO Helical Coil)
Device
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Phase 4 Interventional

Trial of NovoSeven® in Haemophilia - Joint Bleeds

NCT00108797
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
eptacog alfa (activated), Feiba VH
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Up to 20 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
20
States / cities
Little Rock, Arkansas • Berkeley, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Not applicable Interventional

Optimizing Treatment of Post-hemorrhagic Ventricular Dilation in Preterm Infants

NCT00875758
View directory record Official record
Conditions
Intraventricular Hemorrhage, Hydrocephalus
Interventions
Removal of CSF through ventricular access device, Removal of CSF through a ventricular access device
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 34 Weeks
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 21, 2026, 7:02 AM EDT
Completed No phase listed Observational

Prevention of Retained-Blood Outcomes With Active Clearance Technology

NCT02145858
View directory record Official record
Conditions
Hemorrhage, Atrial Fibrillation, Postoperative
Interventions
Blood drainage post cardiac surgery using PleuraFlow System
Device
Lead sponsor
ClearFlow, Inc.
Industry
Eligibility
18 Years and older
Enrollment
891 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Manchester, New Hampshire • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors

NCT04158648
View directory record Official record
Conditions
Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor, Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 21, 2026, 7:02 AM EDT
Completed No phase listed Observational

Study to Determine the Accuracy of Prothrombin Time of Warfarinised Blood

NCT01375725
View directory record Official record
Conditions
Clotting Disorders
Interventions
Not listed
Lead sponsor
Universal Biosensors Pty Ltd
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Batesville, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2011 · Synced Oct 21, 2026, 7:02 AM EDT
Completed No phase listed Observational

Familial Myeloproliferative Disorders

NCT00666289
View directory record Official record
Conditions
Polycythemia Vera, Essential Thrombocythemia, Idiopathic Myelofibrosis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
7 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Effects of CoSeal on Bleeding & Adhesions in Pediatric Heart Surgery

NCT01330433
View directory record Official record
Conditions
Congenital Heart Defect, Surgery-Induced Tissue Adhesions, Hemorrhage
Interventions
CoSeal Surgical Spray Group
Device
Lead sponsor
Loma Linda University
Other
Eligibility
Up to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Myelofibrosis

NCT00039416
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis
Interventions
imatinib mesylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures

NCT00618098
View directory record Official record
Conditions
Reversal of Anticoagulant Treatment
Interventions
Octaplex (human prothrombin complex concentrate), Fresh frozen plasma
Biological
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 21, 2026, 7:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery

NCT04660721
View directory record Official record
Conditions
Hemostasis, General Surgery
Interventions
sFilm-FS, TACHOSIL®
Combination Product
Lead sponsor
Sealantium Medical Ltd.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 21, 2026, 7:02 AM EDT
Completed No phase listed Observational

Evaluation of the Quantra QStat System in Obstetric Patients

NCT05875987
View directory record Official record
Conditions
Blood Loss Massive, Post Operative Hemorrhage
Interventions
Quantra System
Device
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Oct 21, 2026, 7:02 AM EDT